- Conditions
- Anemia in Chronic Kidney Disease
- Interventions
- FMX-8
- Drug
- Lead sponsor
- FerruMax Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Diseases, Patient Requiring Heparin Free Dialysis Treatments
- Interventions
- Dialyzer with Endexo
- Device
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- New Bern, North Carolina
- Conditions
- Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
- Interventions
- Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
- Drug
- Lead sponsor
- James A. Tumlin, MD
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Lawrenceville, Georgia • Bethlehem, Pennsylvania
- Conditions
- Kidney Failure, Chronic
- Interventions
- Intradialytic exercise
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy, BK Virus (Nephropathy), Antibody-mediated Rejection, Acute Cellular Graft Rejection
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 445 participants
- Timeline
- 2017 – 2026
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
- Conditions
- Acute Kidney Injury
- Interventions
- Iopamidol 300 (Contrast), Placebo (Normal Saline)
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri
- Conditions
- Chronic Kidney Disease
- Interventions
- Sevelamer hydrochloride, Calcium-based phosphate binder
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 72
- States / cities
- Gadsden, Alabama • Huntsville, Alabama • Tucson, Arizona + 63 more
- Conditions
- End Stage Renal Disease
- Interventions
- Group 1: GranuFlo, Group 2: NaturaLyte
- Device
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- End-Stage Renal Disease
- Interventions
- Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 20 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- LHW090, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
- Conditions
- Chronic Kidney Disease, Hypertension
- Interventions
- outpatient clinic kidney-protective care
- Other
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2024
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis
- Interventions
- Sodium ferric gluconate,
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 29
- States / cities
- Bakersfield, California • Glendale, California • Los Angeles, California + 26 more
- Conditions
- Chronic Kidney Diseases, Obstructive Sleep Apnea
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 555 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- eltrombopag
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Saint Paul, Minnesota
- Conditions
- Chronic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Chronic Kidney Disease (Stages 4 and 5)
- Interventions
- Kidney RISE
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • New York, New York
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Eden Prairie, Minnesota
- Conditions
- Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes, Arthritis, Cancer, Peripheral Arterial Disease, Parkinson's Disease, End Stage Renal Failure on Dialysis
- Interventions
- MBB AFO, Control
- Device · Other
- Lead sponsor
- Bijan Najafi, PhD
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- CBD, Transplant Complication, Kidney Disease, Chronic
- Interventions
- Tacrolimus single dose, Epidiolex single dose, Epidiolex steady-state and tacrolimus single dose
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hypertension, Renal Insufficiency, Chronic
- Interventions
- Clinical Decision Support System (CDSS), Clinic Decision Sup System + Pharmacist
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Anemia, Renal Insufficiency, Chronic
- Interventions
- Molidustat (BAY85-3934), Epoetin alfa/beta
- Drug · Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Azusa, California • Long Beach, California • Lynwood, California + 16 more
- Conditions
- Kidney Failure, Chronic
- Interventions
- Lanthanum Carbonate, Sevelamer
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- End Stage Kidney Disease (ESRD)
- Interventions
- The Amplifi System is a temporary extracorporeal blood pump designed to deliver controlled flow through a peripheral vein for 24-72 hours prior to AVF creation., Standard of Care (AVF creation)
- Device · Procedure
- Lead sponsor
- Amplifi Vascular, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas